FDA to give Schering program priority review

Schering-Plough says the FDA will provide a priority review for sugammadex, which is being developed to reverse the effects of anesthesia used during surgery. Schering-Plough says the drug is significantly different than the meds already on the market for reversing the effects of anesthesia, saying the drug works for both mild and serious anesthesia induced by muscle relaxants. The priority review will cut the FDA's review process from 10 months to six.

- read the release for more info

ALSO: Schering-Plough plans to expand its manufacturing operations in Miami. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.